

ANTITUBERCULOSIS DRUG - INDUCED ELEVATION IN SERUM ALANINE AMINOTRANSFERASE (ALT) LEVELS: A COMPARISON BETWEEN PATIENTS WITH AND WITHOUT HIV SEROPOSITIVITY IN YENAGOA, NIGERIA

ABSTRACT

INTRODUCTION: The prevalence of rifampicin, isoniazid and pyrazinamide induced elevations in serum alanine aminotransferase (ALT) levels were compared in a cohort of Nigerians with and without HIV seropositivity.

METHOD: Records of all the patients with pulmonary tuberculosis (251 HIV positive and 205 HIV negative), aged above 15years treated in the TB program of the Federal Medical Centre, Yenagoa from January 2013 to December 2014 were analysed for this study. The WHO 4 grades of hepatotoxicity using ALT were used. ALT of less than 50U/L was taken as normal. Grade 1 (very mild hepatotoxicity): $<2.5 \times$ upper limit of normal (ULN) i.e. ALT 51-125 U/L. Grade 2 (mild): $2.6 - 5 \times$ the ULN (ALT 126-250 U/L). Grade 3 (moderate): $5-10 \times$ the ULN (ALT 251 – 500 U/L). Grade 4 (severe) $>10 \times$ the ULN (ALT > 500 U/L)

RESULTS:

No patient with or without HIV seropositivity had ALT value in the grade 3 and 4 category. There was no statistically significant difference in ALT values between cohorts with or without HIV in the 3 ALT phase obtained while on antituberculous drugs ($P = 0.761, 0.367$ and 0.197)

CONCLUSION

All the observed hepatotoxicity were mild. The average rate of hepatotoxicity in the HIV uninfected pulmonary tuberculosis cohort was 16.6%, 9.8% and 5.4% for ALT₁, ALT₂ and ALT₃ respectively. The rate in the HIV infected cohorts was 15.5%, 8.8% and 16.4% for ALT₁, ALT₂ and ALT₃. It is encouraging to find a low rate of antituberculosis drug induced hepatotoxicity than one would expect based on the high prevalence of risk factors in our environment.

KEY WORDS: Tuberculosis, antituberculosis drugs, HIV, HAART, Alanine aminotransferase (ALT).

1. **BACKGROUND**

It has been reported that the response to antituberculosis (TB) treatment among HIV co-infected patients is generally good, though many require concurrent highly active antiretroviral therapy (HAART) to achieve a successful long term outcome.^{1,2} It has also been

reported that HIV/TB co-infected patients experience a higher rate of adverse drug reactions to treatment than those without HIV.³

However, active TB disease requires prompt initiation of TB treatment. The treatment of active TB disease in HIV infected patients should follow the general principles for individual without HIV. Treatment of drug susceptible TB disease should include a standard regimen that consist of first-line drugs-isoniazid, rifampicin, pyrazinamide and ethambutol given for 2 months, followed by isoniazid and rifampicin/ethambutol for 4 to 6 months^{1,2,3}. All HIV positive patients with active TB disease should start antiretroviral treatment (ART). However, in patients with HIV-related tuberculosis, treating tuberculosis is the first priority.² In the setting of advanced HIV infection, untreated tuberculosis can progress rapidly to death. Anti-retroviral treatment may be lifesaving for patients with advanced HIV infection. Consequently, concurrent treatment may be necessary in patients with advance HIV disease (e.g circulating CD4 lymphocytes count < 200/UL). The newest policy guidelines from WHO recommends that ART should be given to all TB/HIV co-infected patients, irrespective of their CD4 cell count (and to all people living with HIV/AIDS with a CD4 cell count less than 500). The concomitant use of anti-TB and antiretroviral (ARV) drugs is complicated by adherence challenge of pill burden, drug-drug interaction, overlapping adverse effects which is one of the serious adverse effect.^{2,4,5,6}

Anti TB drug induced hepatotoxicity is one of the most challenging problems and main cause of treatment interruption during TB treatment course that causes hospitalization and life-threatening events in other spheres.^{6,7,8} Among the first line anti-TB drugs pyrazinamide, isoniazid and rifampicin have been associated with hepatotoxicity and the risk is enhanced when the drugs are used in combination.⁹ Prevalence rate of hepatotoxicity in TB patients on treatment in different studies have varied from 1-31%.¹⁰⁻¹⁴ The National Tuberculosis and Leprosy Control Programme (NTBLCP) recommends efavirenz based(Tenofovir, Lamivudine and Efavirenz) HAART regimen in all HIV-positive TB patients to reduce drug interactions with rifampicin.²

We sought to compare anti-tuberculosis drug induced elevation in ALT between patients with and without HIV seropositivity in our patients since ALT is the most commonly used marker for liver injury. Although ALT is produced by other organs it is found predominantly in hepatocytes and is considered a specific marker for liver injury¹⁵.

2. METHODS

2.1 Design: A retrospective cohort analysis of all collected medical records of adults (>15 years) patients seen in the ART/TB clinic of the Federal Medical Centre, Yenagoa between January 2013 and December 2014 was carried out using a standardized data extraction form. The demographic, clinical and laboratory parameters of patients were retrieved and analysed and these included smear status of AFB, chest radiograph where necessary, ALT₁ at baseline, ALT₂ at 4 weeks and ALT₃ at 8 weeks

85 after commencement of anti-tuberculosis drugs. Those patients that had completed
86 anti-tuberculosis drugs were excluded.

87

88 2.2 **Setting:** the study was undertaken in Federal Medical Centre, Yenagoa a Tertiary
89 referral hospital in Bayelsa State, South-South, Nigeria. The HIV/AIDS treatment
90 centre, situated within the hospital premises and supported by USAID/FHI 360 and
91 NTBLCP, offers comprehensive HIV treatment and care to such patients free of
92 charge. They also provide drugs free of charge to patients with pulmonary
93 tuberculosis.

94

95 2.3 **Diagnosis:** The diagnosis of HIV/AIDS was based on WHO guidelines.^{16,17} The
96 diagnosis of pulmonary tuberculosis (PTB) required positive sputum acid fast bacilli
97 or compatible clinical features and suggestive chest radiograph findings. Alanine
98 aminotransferase (ALT) measurement was done with automatic biochemistry
99 analyser (Horiba Medical, France). Human immunodeficiency virus (HIV) test was
100 done by two serial testing using rapid test kit (Determine, Abbot Laboratories, UK)
101 and confirmed by Western blot technique (Immunetika Qualicole,USA).

102

103 2.4 **Statistical analysis:** The data were analysed using the EPI-INFO 2012 statistical
104 program version 7.0.9.34. Continuous variables were described with mean and
105 standard deviation, while discontinuous variables were described with proportions.
106 The Mann-Whitney test was used when comparing groups of cohort. At 95%
107 confidence limit P-value less than or equal to 0.05 were considered to be significant.

108

109 2.5 **Ethics Statement:** Approval for conducting the study was obtained from the hospital
110 Ethics committee. Patient consent was not obtained due to the retrospective nature
111 of the study and any personally identifiable information was not collected and made
112 available to maintain confidentiality.

113

114 3. RESULTS

115

116 3.1 A total of 470 adults pulmonary tuberculosis patients were attended to in the period
117 under review. Of this number 6 deaths were recorded for reasons other than
118 possible drug-induced hepatotoxicity, while 5 patients defaulted and 3 patients were
119 transferred out. These 14 patients were excluded from the study. The rest 456
120 patients consisted of 251 HIV positive and 205 HIV negative individuals. Table 1
121 shows the characteristics of the patients.

122

123 Antituberculosis drug induced elevation in ALT: a comparison between patients with
124 and without HIV sero-positivity

125

Table 1: Age, Gender and ALT distribution of study population

Variable	PTB only n=205	PTB/HIV co-infection n=251
Age (median and IQR)	32 (17.61)	31(15.65)
Gender (N/%)		
M	57 (27.8)	68 (27.1)
F	148 (72.2)	183 (72.9)
ALT ₁ (N/%)		
0 – 50 U/L	171 (83.4)	212 (84.5)
51 – 125 U/L	30 (14.6)	34 (13.5)
126 – 250 U/L	4 (2)	5 (2.0)
Mean rate of hepatotoxicity	16.6%	15.5%
ALT ₂ (N/%)		
0 – 50 U/L	185 (90.2)	229 (91.2)
51 – 125 U/L	18 (8.8)	20 (8.0)
126 – 250 U/L	2 (1.0)	2 (0.8)
Mean rate of hepatotoxicity	9.8%	8.8%
ALT ₃ (N/%)		
0 – 50 U/L	194 (94.6)	235 (93.6)
51 – 125 U/L	11 (5.4)	15 (16.0)
126 – 250 U/L	0 (0.0)	1 (0.4)
Mean rate of hepatotoxicity	5.4%	16.4%

3.2 For all the 3 groups (ALT₁, ALT₂ & ALT₃) majority of the patient were in the 0-50 U/L range i.e. no hepatotoxicity. No patient fell in the 251-500 U/L and > 500 U/L ranges. There was no statistically significance difference between the HIV infected and HIV uninfected cohorts in the ALT₁, ALT₂ and ALT₃ measurements. P = 0.761, 0.367 and 0.197 respectively.

Table 2: Comparison of ALT levels in patients with PTB only and PTB/HIV Co-infection.

Variable	PTB only	PTB/HIV Co-infection	P value
----------	----------	----------------------	---------

	(n= 205)	(n= 251)	Z-test
Age (years)	33.43±8.10	33.33±9.43	P=0.660
ALT ₁ (U/L)	33.02±24.28	33.80±28.82	P=0.761
ALT ₂ (U/L)	29.74±18.36	30.21±16.98	P=0.367
ALT ₃ (U/L)	26.40±14.39	27.82±15.00	P=0.197

NB: Results are given as Mean ±SD with range in parenthesis.

DISCUSSION

To our knowledge this is the first analysis of hepatotoxicity using serum alanine aminotransferase ALT in an African HIV and TB treatment program. HIV infection is a risk factor for anti- tuberculosis drug induced hepatotoxicity, so is the use of HAART.^{18, 19} In our study there was no statistically significant difference between ALT levels between the HIV infected and HIV uninfected group at baseline, 4 weeks, 8 weeks after commencement of antituberculosis drugs.

The low proportion of antituberculosis drug-induced hepatotoxicity (ATDH) in our study is consistent with previous studies in sub-saharan African.^{20,21,22} In a study in Congo DR, TB drug (2HRZE/4HR) were well tolerated among 446 TB patients. They did not report any hepatitis, but increased transaminases levels were occasionally seen.²¹ Similarly, in study done in Uganda, only two of 265 HIV infected subjects (1%) developed hepatotoxicity during treatment of pulmonary TB with 2HRZE/6HR.²² Some workers reported that hepatitis and transaminases elevation did occur during preventive TB treatment in HIV- positive patients and that 0.80% had transaminase levels > 135U/L.²³

All these reports suggest that the incidence of antituberculosis drug-induced hepatotoxicity (ATDH) in adults is low in sub-Saharan Africa. This is unexpected because risk factors such as HIV, hepatitis B and C infection are highly prevalent in this region. The reasons for this low incidence of ATDH are varied. For example, the available studies were not designed to specifically study ATDH, thus, mild or transient hepatotoxicity may have been missed.²⁰ Furthermore, there is some evidence that absorption of anti- TB drugs in adults with HIV/AIDS is worse compared with non-HIV infected patients.²⁴ This could explain why ATDH is seen less frequently in our HIV infected population even when HIV infection is a risk factor for ATDH. Some workers have cited the possibility of ethnic variation causing differences in susceptibility to drug toxicity. Phenotypic variation in human drug metabolism can be attributed to polymorphism in genes encoding drug metabolising enzymes. Such polymorphisms may alter enzymes activity and could subsequently increase formation of reactive metabolites.²⁵ Genetic polymorphism in drug metabolising enzymes may explain the low incidence of ATDH in sub-Saharan populations.

These findings make further studies on ATDH attractive especially if directed specifically at the subject of antituberculosis drug induced liver injury (even when on HAART) and why the incidence is low in our population.

The NGO that was making anti-tuberculosis drugs and HAART available was also responsible for the cost of carrying out ALT estimations at no cost to the patients. A more elaborate liver function would have been much better in a study of this nature. This is the first limitation. Secondly, is the limitation inherent in retrospective studies which means that validated cause of death could not be ascertained.

CONCLUSION: The incidence of antituberculosis drug-induced hepatotoxicity is low in our cohort of both HIV infected and uninfected individuals and that this requires further studies to ascertain reason for this unexpected findings

References

1. Kwara A, Flanigan R.P, Carter E.J. highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status, International Journal of Tuberculosis and Lung Disease 2005;9:248-254
2. National Tuberculosis, Leprosy and Buruli ulcer Management and control Guidelines Sixth Edition 2014. Federal Ministry of Health, Nigeria.
3. Yee D, Valiquette C, Pelletier M et al. Incidence of serious side effects from first line antituberculous drugs among patients treated for active tuberculosis. Am. J. Respir Crit Care Med. 2003; 167:1472-7.
4. Burman W, issues in the management of HIV related tuberculosis Chin Chert Med 2005; 26:283-294.
5. Verina J.K., Nateniyon S., Mankatiriviham W, Sirinak C et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMG Infect Dis. 2009; 9: 42. Doi 10.1186/1471-2334-1189-1142.
6. Lee WM. Dmg-induced Hepatotoxiaty N Eng J. Med 349:474-485
7. Burman W.J, Reves R, Hepatotoxiaty from refampicin plus pyrazinamide: lessons for policy makers and messages for care providers. Am. J. Respir Crit Care med 2001. 164-1112-1113.

- 214 8. Walker U. Antiretroviral therapy induced liver alteration. Curr Opin HIV/AIDS 2007.
215 2:293-298.
- 216 9. Merveron H, Meintjes G, Burman WJ, Maartens G. Complicatioons of antiretroviral
217 therapy in patients with tuberculosis drug interactions, toxicity and immune
218 reconstitution inflammatory syndnome. J. Infect Dis 2007 196:863-75.
219
- 220 10. Getnet Yimer, Getachew Aderaye, Wondnossen Amogne, Eyasu Makonnen, Eleni
221 Akhillu et al. Anti-tuberculosis therapy-induced Hepatotoxiaty among Ethiopian HIV
222 positive and Negative Patients 2008. PLOS one 3: e 1809.
223
- 224 11. Tostman A, Boerce MJ, Aarnoutse RE, de-Lange WC, Van der Van AJ et al.
225 Antituberculosis drug induced hepatotoxiaty. Concise up to date review J. Gastroen-
226 Hepatic 2008. 23. 192-202.
227
- 228 12. Khalili H, Dastiti-Khavidaki S. Rasoo/Mejad M, Rezaie L, Antituberculosis drugs
229 related hepatotoxicity, incidence, risk factor, pattern of changes in liver energies and
230 outcome DARU. 2009; 17;163-167.
231
- 232 13. Javadi MR. Shalviri G, Gholami K. Salam Zadeh J, Maghooli G et al. Adverse reactions
233 of antituberculosis drug in hospitalized patients. Incidence, severity and risk factor.
234 Pharmaco epidemol drug saf. 2007; 16: 1104-1110.
- 235 14. Shang P, Xiz Y, Liu F, Wong X, Yiian Y et al incidence, clinical features and impact on
236 antituberculosis treatment of anti-tuberculosis drug induced liver injury (ALT) in
237 China. PLOS One 2011;6:e21836. doi: 21810 213711 journal pone 0621836.
238
- 239 15. Ruhl CE, Ever hart JE, Elevated Serum Alanine Aminotransferase and gamma
240 glutamyl transferase and mortality in the United State Population. Gastroenterology
241 2009: 136: 477-485.
242
- 243 16. WHO Antiretroviral therapy for HIV infection in adults and adolescent:
244 Recommendation for public health approval, Revision. 2006. Available:
245 <http://www.who.int/en/>
246
- 247 17. National Agency for control of AIDS (NACA) National HIV/AIDS. Response Fact Sheet
248 2011. Update on HIV/AIDS Epidemic and Response in Nigeria: 2012. Available:
249 <http://w.w.w.naca.gov.ng/>
250
- 251 18. WHO. International Monitoring of Adverse Reaction to Drugs Adverse Reaction
252 Terminology. Uppsala: WHO Collaborating Centre for International Drug Monitoring.
253 1992.
254

- 255 19. Yee D, Valiquette C, Pelletier M, Parison I, Rocher I, Menzies D, Incidence of serious
256 side effects from first line ant-tuberculosis drug among patients treated for active
257 tuberculosis. Am J. Resp and Critical Care Medicine 2003; 167:1472-1477.
258
- 259 20. Tostman A, Boeree MJ, Harries AD, Saurageot D, Banda HT, Zijlstra EE.
260 Antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected
261 pulmonary tuberculosis patients in Malawi. Tropical Medicine and International
262 Health. 2007;12;7:852-855.
263
- 264 21. Perneins JH, St Louis ME, Mukadi YB, Pulmonary tuberculosis in HIV-infected patients
265 in Zaire. A controlled trial of treatment for either 6 or 12 months NEJM 332:779-784.
266
- 267 22. Johnson JL, Okwara A, Nsubaga P, Efficacy of an unsupervised 8 months rifampicin –
268 containing regimen for the treatment of pulmonary tuberculosis in HIV infected
269 adults. Uganda Case Western Reserve University Research Collaboration. The
270 international Journal of tuberculosis and Lung Disease 200. 4-1032-1040.
271
- 272 23. Whalen CC, Johnson JL, Okwara A. A trial of tree regimens to prevent tuberculosis in
273 Ugandan adults infected with the human immunodeficiency virus. Ugandan Case
274 Western Reserve University Research Collaboration. NESM 1997. 337:801-808.
275
- 276 24. Peloquin CA, Nilta AT, Burman WJ, Low antituberculosis drug concentrations in
277 patients with AIDS. The Annuals of pharmacotherapy. 1996; 30:919-925.
- 278 25. Wilkinson GR. Drug Metabolism and variability among patients in drug response,
279 NEJM. 2005;352:2211-2221